Theravance Biopharma Aktie [WKN DE: A1137V / ISIN: KYG8807B1068]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Theravance Biopharma Inc When Issued

29.01.18		Theravance Biopharma and Mylan Announce FDA Acceptance of New Drug Application for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease (PR Newswire)
28.11.17		Theravance Biopharma Highlights Submission of Landmark IMPACT Data to FDA to Support Expanded Label for Trelegy Ellipta (PR Newswire)
21.11.17		Theravance Biopharma to Present at Two Upcoming Investor Conferences (PR Newswire)
16.11.17		Theravance Biopharma Highlights Marketing Authorization in Europe for Trelegy Ellipta as Once-Daily Single Inhaler Triple Therapy for the Treatment of COPD (PR Newswire)
13.11.17		Theravance Biopharma and Mylan Submit New Drug Application to FDA for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease (PR Newswire)
13.11.17		Theravance Biopharma and Mylan Submit New Drug Application to FDA for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease (PR Newswire)
07.11.17		Theravance Biopharma, Inc. Reports Third Quarter 2017 Financial Results and Provides Business Update (PR Newswire)
01.11.17		Theravance Biopharma and Mylan Report Additional Positive Phase 3 Data for Revefenacin (TD-4208) in Multiple Presentations at 2017 CHEST Annual Meeting (PR Newswire)
01.11.17		Theravance Biopharma and Mylan Report Additional Positive Phase 3 Data for Revefenacin (TD-4208) in Multiple Presentations at 2017 CHEST Annual Meeting (PR Newswire)
01.11.17		Theravance Biopharma Announces Opening of Company's New Corporate Office in Dublin, Ireland (PR Newswire)
01.11.17		Theravance Biopharma Announces Opening of Company's New Corporate Office in Dublin, Ireland (PR Newswire)
31.10.17		Theravance Biopharma Reports Positive New VIBATIV® (telavancin) Data from TOUR™ Observational Patient Registry at 2017 CHEST Annual Meeting (PR Newswire)
30.10.17		Theravance Biopharma to Report Third Quarter 2017 Financial Results on November 7, 2017 (PR Newswire)
25.10.17		CLSD Progressing With TYBEE, SNY In Legal Spat With MYL, TBPH On Watch (RTTNews)
24.10.17		Theravance Biopharma to Present New Data from Studies of VIBATIV® (telavancin) and Revefenacin (TD-4208) at the 2017 CHEST Annual Meeting (PR Newswire)
09.10.17		Theravance Biopharma Reports Positive New Data from Multiple Studies of VIBATIV® (telavancin) at IDWeek™ 2017 (PR Newswire)
03.10.17		Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV® (telavancin) at IDWeek™ 2017 (PR Newswire)
20.09.17		Theravance Biopharma Highlights Positive Headline Results from IMPACT Study of Trelegy Ellipta Announced by GlaxoSmithKline and Innoviva (PR Newswire)
19.09.17		Theravance Biopharma to Present at the Cantor Fitzgerald Global Healthcare Conference (PR Newswire)
19.09.17		Theravance Biopharma Highlights Approval of Trelegy Ellipta (Closed Triple) as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Appropriate Patients with COPD in the US (PR Newswire)
19.09.17		TIBCO Connected Intelligence Cloud Equips Companies for Digital Transformation (PR Newswire)
18.09.17		Theravance Biopharma Highlights GlaxoSmithKline and Innoviva's Receipt of Positive Opinion from CHMP in Europe for Trelegy Ellipta (Closed Triple) (PR Newswire)
05.09.17		Theravance Biopharma to Present at the Morgan Stanley 15th Annual Global Healthcare Conference (PR Newswire)
15.08.17		Gainers & Losers Of Aug.14: TTOO, TBPH, SGMO, APEN, ZYNE... (RTTNews)
10.08.17		Gainers & Losers Of Aug.9: NTRA, ACHN, OMER, SGRY, PGNX... (RTTNews)
09.08.17		ACHN Soars On PNH Data, ACAD Abuzz, ALDR On Track, Zealand To Debut On Nasdaq (RTTNews)
08.08.17		Theravance Biopharma, Inc. Reports Second Quarter 2017 Financial Results and Provides Business Update (PR Newswire)
08.08.17		Theravance Biopharma Reports Encouraging Data from First Cohort of Patients in Phase 1b Clinical Trial of TD-1473 in Ulcerative Colitis (PR Newswire)
03.08.17		FDA Panel Snubs JNJ, CHMP Seeks More Data From PBYI, TBPH On Watch, AGRX Slumps (RTTNews)
02.08.17		Theravance Biopharma Announces Positive Top-Line Results from Phase 2b Study of Velusetrag (TD-5108) in Patients with Gastroparesis (PR Newswire)
01.08.17		Theravance Biopharma to Report Second Quarter 2017 Financial Results and Business Update on August 8, 2017 (PR Newswire)
31.07.17		Theravance Biopharma Appoints Shehnaaz Suliman, MD, as Senior Vice President of Corporate Development and Strategy (PR Newswire)
20.07.17		SRPT Soars On Q2 Results & Outlook, AERI's Mercury-1 Does An Encore, ALIM Abuzz (RTTNews)
19.07.17		Theravance Biopharma and Mylan Announce Positive Results from 12-Month Phase 3 Safety Study of Revefenacin (TD-4208) in Patients with Chronic Obstructive Pulmonary Disease (COPD) (PR Newswire)
19.07.17		Theravance Biopharma and Mylan Announce Positive Results from 12-Month Phase 3 Safety Study of Revefenacin (TD-4208) in Patients with Chronic Obstructive Pulmonary Disease (COPD) (PR Newswire)
05.06.17		New Data Highlighting in vitro Potency Advantages for VIBATIV® (telavancin) Against Difficult-to-Treat MRSA and MSSA Pathogens Reported at ASM Microbe 2017 (PR Newswire)
23.05.17		Theravance Biopharma and Mylan Report Additional Phase 3 Data for Revefenacin (TD-4208) in Several Presentations at 2017 ATS (PR Newswire)
23.05.17		Theravance Biopharma and Mylan Report Additional Phase 3 Data for Revefenacin (TD-4208) in Several Presentations at 2017 ATS (PR Newswire)
17.05.17		Theravance Biopharma and Mylan to Present Additional Data for Revefenacin (TD-4208) in Several Presentations at 2017 ATS (PR Newswire)
10.05.17		ARRY Hits Trial Goals, DEPO Falls On Q1 Results, SAGE Awaits Data In Q3 (RTTNews)
09.05.17		Theravance Biopharma, Inc. Reports First Quarter 2017 Financial Results and Provides Business Update (PR Newswire)
02.05.17		Theravance Biopharma to Report First Quarter 2017 Financial Results on May 9, 2017 (PR Newswire)
27.04.17		Theravance Biopharma to Present at the Deutsche Bank 42nd Annual Health Care Conference (PR Newswire)
25.04.17		New Data for VIBATIV® (telavancin) Reported in Several Presentations at ECCMID 2017 (PR Newswire)
24.04.17		Theravance Biopharma Reports Positive Clinical Response Rates for Patients in TOUR™ Observational Patient Registry in Several Presentations at ECCMID 2017 (PR Newswire)
18.04.17		Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV® (telavancin), Including Preliminary Results from TOUR™ Observational Patient Registry, at 2017 ECCMID Conference (PR Newswire)
13.04.17		Nintex Announces 6th Annual Partner Awards (PR Newswire)
28.03.17		Theravance Biopharma to Present at the 16th Annual Needham Healthcare Conference (PR Newswire)
17.02.17		Theravance Biopharma Presents Positive Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization (PR Newswire)
15.02.17		Theravance Biopharma to Report Fourth Quarter and Full Year 2016 Financial Results on February 27, 2017 (PR Newswire)

Zurück | 1 | 2 | Weiter

Newssuche

Meistgelesene Nachrichten

Krypto-Influencer prognostiziert für 2025 gewaltige Rally beim Dogecoin

Solana Kurs-Prognose: 300 US-Dollar noch im Januar?

Krypto-News: Während der Bitcoin konsolidiert pumpen Solana, Ripple und der Dogecoin

Bitcoin vor Gold? Bernstein-Analyst sieht Potenzial für Ablösung

Neuer Stablecoin RLUSD: Ripple setzt auf globale Verfügbarkeit

KI-Entwicklungen steigern Optimismus: Analysten bullish für Amazon

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	07.01.2025 07:31
Kaufwert:	EUR
	Hinzufügen Speichern